Dry Powder Inhalers - Key Annual Conference for Pharmaceutical & Medical Device Professionals in the DPI Market (London, United Kingdom - June 24-25, 2020) - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 31, 2020--
The “Dry Powder Inhalers - Key Annual Conference for Pharmaceutical and Medical Device Professionals in the DPI Market” conference has been added to ResearchAndMarkets.com’s offering.
The second generation of DPIs have become either established on the market or are a significant way along the approval process. These have been a great success story in improving inhaled drug delivery. However, we now have to tackle the technical and regulatory issues with generic’ inhalers and their approval.
The development of triple therapies is well underway and these bring about their own challenges of formulation and bioequivalence.
Amazingly, new DPIs are still being created, with some moving into development programmes. One of the areas where much study and recent guidance has been applied is in considering the patient use, compliance and human factors associated with DPIs. These linked topics are creating a whole new area that requires better understanding during product development and associated studies.
The Dry Powder Inhalers conference will address many of the issues around generic inhalers, provide case studies of bioequivalence testing, focus on the difficult formulation challenges and the strategies used so that they may be overcome, and discuss in-depth patient and human factor issues when developing a DPI to gain regulatory approval.
Conference programme to include:
Programme Day One
Current and future challenges for DPI formulations
Novel DPI delivery platforms
Design and characterisation of breath actuation mechanisms (BAMs)
Methods for the determination of delivered-dose uniformity and aerodynamic particle size distributions of DPIs
Sampling and analysis of inhalation devices in accordance with ISO 18562
Development of a new moisture-resistant DPI which performs well irrespective of orientation
How can the physicochemical properties of DPIs and their stability impact product performance? A process and delivery perspective
Spray drying of nanopharmaceuticals into microsphere formulations
Programme Day Two
INFORM 2020: new analytical insights into dry powder formulations for inhalation
Dry powder formulations: from low dosage API delivery to biopharmaceuticals
Inhalation products, transitioning from less to more regulated markets, can it be that difficult?
Formal product characterization studies required for DPI’s
Overcoming the need for comparative clinical endpoint bioequivalence studies in a 505(j) ANDA weight of evidence approach for orally inhaled products
Dr Rob Price
The 1nhaler and its two jobs
Opportunities and challenges in the design of a high-performance unit-dose DPI
For more information about this conference visit https://www.researchandmarkets.com/r/dhp6tg
View source version on businesswire.com:https://www.businesswire.com/news/home/20200131005179/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 01/31/2020 05:09 AM/DISC: 01/31/2020 05:09 AM